Neltenexine (CAS 99453-84-6) Global Market Research Report 2024

About the Neltenexine Market

Neltenexine is a respiratory drug used to treat asthma and chronic obstructive pulmonary disease (COPD). It is a long-acting muscarinic antagonist (LAMA) that works by blocking the action of a chemical messenger in the lungs, which helps to reduce the narrowing of the airways. Neltenexine is available in both inhaler and tablet form, and is typically prescribed as a maintenance therapy for those with moderate to severe asthma or COPD. It is also used as an add-on therapy for those who are not adequately controlled on other medications. Neltenexine is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2019. It is currently marketed by several pharmaceutical companies, including GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca. It is also available in generic form from several generic drug manufacturers. Neltenexine is a promising treatment option for those with asthma and COPD, offering a long-acting and effective therapy. It is becoming increasingly popular as a maintenance therapy for those with moderate to severe asthma or COPD, and is also being used as an add-on therapy for those who are not adequately controlled on other medications. Companies in the Neltenexine market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and several generic Show Less Read more